Curto, ElenaMunteis-Olivas, ElviraBalcells Vilarnau, Eva, 1967-Domínguez Álvarez, Marisol2023-12-112023-12-112016Curto E, Munteis-Olivas E, Balcells E, Dominguez-Alvarez MM. Pulmonary eosinophilia associated to treatment with natalizumab. Ann Thorac Med. 2016 Jul-Sep;11(3):224-6. DOI: 10.4103/1817-1737.1857621817-1737http://hdl.handle.net/10230/58490Natalizumab (Tysabri(®)) is a leukocytes chemotaxis inhibitor that decreases the leukocytes passage through the hematoencephalic barrier and it is currently used in relapsing-remitting forms of multiple sclerosis (MS). We present a patient with allergic rhinoconjunctivitis diagnosed with MS who started treatment with natalizumab. She began to show mild asthmatic symptoms until she needed admission to the hospital due to respiratory insufficiency. Blood tests showed peripheral eosinophilia and the thoracic computed tomography scan demonstrated pulmonary infiltrates. The bronchoscopy with the bronchoalveolar lavage resulted in eosinophilic alveolitis. No evidence of bacterial, fungal and parasitic infection, connective tissue disease, or vasculitis were observed. After discontinuation of natalizumab, the patient improved without other treatments. As MS is a prevalent disease and the use of natalizumab is increasing, we consider important to point out that this drug can be associated with pulmonary eosinophilia, especially in patients with allergic rhinoconjunctivitis or asthma.application/pdfeng© 2016 Annals of Thoracic Medicine. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.info:eu-repo/semantics/articlehttp://dx.doi.org/10.4103/1817-1737.185762Multiple sclerosisNatalizumabPulmonary eosinophiliainfo:eu-repo/semantics/openAccess